Pharmaceutical giant Eli Lilly is reportedly in advanced discussions to acquire Kelonia Therapeutics in a deal valued at over $2 billion. The potential acquisition was first reported by the Wall Street Journal.

Pharmaceutical giant Eli Lilly is reportedly close to acquiring Kelonia Therapeutics in a deal valued at over $2 billion, aiming to bolster its cancer treatment pipeline.